Orion subsidiary invests 82.5B KRW in Ligachem Bio
오리온
271560
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=703
Risk-adjusted indicator based on 703 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Acquisition Amount: 82,499,895,400 KRW
- • Acquired Shares: 552,578 Shares
- • Post-acquisition Ownership: 9,915,861 Shares (25.28%)
- • Acquisition Ratio to Total Assets: 1.79%
- • Ligachem Bioscience 2023 Net Income: -91,552M KRW
AI Analysis Summary
Orion Corp.'s overseas subsidiary, PAN ORION Corp. Limited, will acquire 552,578 convertible preferred shares of Ligachem Bioscience for 82.5B KRW through a third-party paid-in capital increase, representing 1.79% of Orion's total assets. Post-acquisition, PAN ORION will hold 9,915,861 shares, equating to a 25.28% stake. The acquisition aims to participate in a cutting-edge strategic industry fund. Ligachem Bioscience reported a net loss of 91,552M KRW in 2023. The investment is long-term, with an acquisition date set for July 24, 2026, and convertible preferred shares having a 10-year duration before automatic conversion to common stock.
How This Event Is Evaluated
M&A / Merger Evaluation
M&A events are evaluated by assessing deal size relative to company scale, strategic rationale, financing structure, and integration risk.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Deal size relative to market value
- Strategic fit and synergy potential
- Financing structure (cash, stock, debt)
- Regulatory and integration risk
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.